AR037299A1 - Uso para eltratamiento de la enfermedad de reflujo gastroesofagico - Google Patents
Uso para eltratamiento de la enfermedad de reflujo gastroesofagicoInfo
- Publication number
- AR037299A1 AR037299A1 ARP020104319A ARP020104319A AR037299A1 AR 037299 A1 AR037299 A1 AR 037299A1 AR P020104319 A ARP020104319 A AR P020104319A AR P020104319 A ARP020104319 A AR P020104319A AR 037299 A1 AR037299 A1 AR 037299A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- cannabinoid receptor
- gastroesophagic
- regurgitation
- inhibition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103936 | 2001-11-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037299A1 true AR037299A1 (es) | 2004-11-03 |
Family
ID=20286096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020104319A AR037299A1 (es) | 2001-11-23 | 2002-11-11 | Uso para eltratamiento de la enfermedad de reflujo gastroesofagico |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7358245B2 (https=) |
| EP (1) | EP1453497A1 (https=) |
| JP (1) | JP2005511632A (https=) |
| KR (1) | KR20050044582A (https=) |
| CN (1) | CN1610542A (https=) |
| AR (1) | AR037299A1 (https=) |
| AU (1) | AU2002353700A1 (https=) |
| BR (1) | BR0214319A (https=) |
| CA (1) | CA2466916A1 (https=) |
| HU (1) | HUP0402080A3 (https=) |
| IL (1) | IL161748A0 (https=) |
| IS (1) | IS7272A (https=) |
| MX (1) | MXPA04004774A (https=) |
| NO (1) | NO20042613L (https=) |
| NZ (1) | NZ532844A (https=) |
| PL (1) | PL369402A1 (https=) |
| RU (1) | RU2280443C2 (https=) |
| TW (1) | TW200407110A (https=) |
| WO (1) | WO2003043619A1 (https=) |
| ZA (1) | ZA200403785B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06004434A (es) * | 2003-10-24 | 2006-06-20 | Solvay Pharm Gmbh | Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos. |
| WO2005060971A1 (en) * | 2003-12-18 | 2005-07-07 | Astrazeneca Ab | Treatment of reflux-related diseases |
| SE0303490D0 (sv) * | 2003-12-19 | 2003-12-19 | Astrazeneca Ab | New use V |
| JP2008517976A (ja) | 2004-10-25 | 2008-05-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｂ１カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病１型、肥満及び関連症状の治療用の医薬組成物 |
| EP1827393A4 (en) * | 2004-12-09 | 2012-04-18 | Insys Therapeutics Inc | AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS |
| WO2008019146A2 (en) * | 2006-08-04 | 2008-02-14 | Insys Therapeutics Inc. | Aqueous dronabinol formulations |
| JP2010535774A (ja) * | 2007-08-06 | 2010-11-25 | インシス セラピューティクス インコーポレイテッド | 経口カンナビノイド液体製剤および治療方法 |
| JP2010540618A (ja) * | 2007-10-02 | 2010-12-24 | アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド | 幼児の成長および発達を増大するための内在性カンナビノイド |
| US20090208588A1 (en) * | 2008-02-19 | 2009-08-20 | Roger Wayne Brown | GERD carbohydrate compositions |
| CN103588672A (zh) * | 2013-10-28 | 2014-02-19 | 史克勇 | 一种治疗癌性疼痛的药物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2735774B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant |
| WO1997029079A1 (en) * | 1996-02-06 | 1997-08-14 | Japan Tobacco Inc. | Novel compounds and pharmaceutical use thereof |
| US5939429A (en) * | 1997-09-30 | 1999-08-17 | Virginia Commonwealth University | Cardiovascular uses of cannabinoid compounds |
| CA2340445A1 (en) | 1998-05-04 | 1999-11-11 | The University Of Connecticut | Novel analgesic and immunomodulatory cannabinoids |
| US6348498B1 (en) | 1998-05-29 | 2002-02-19 | Neurosciences Research Foundation, Inc. | Control of pain with endogenous cannabinoids |
| GB9923738D0 (en) | 1999-10-07 | 1999-12-08 | Nestle Sa | Nutritional composition |
| IL132661A (en) * | 1999-10-31 | 2008-11-26 | Raphael Mechoulam | Agonists specific for peripheral cannabinoid receptors |
| SE9904507D0 (sv) * | 1999-12-09 | 1999-12-09 | Astra Ab | New compounds |
| ES2291323T3 (es) * | 2000-06-15 | 2008-03-01 | Schering Corporation | Antagonistas de receptores de trombina. |
| AUPR118000A0 (en) * | 2000-11-02 | 2000-11-23 | Amrad Operations Pty. Limited | Therapeutic molecules and methods |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| US20020077322A1 (en) * | 2000-12-15 | 2002-06-20 | Ayoub George S. | Protection of neurons against glutamate-induced damage in glaucoma and other conditions |
-
2002
- 2002-11-07 TW TW091132760A patent/TW200407110A/zh unknown
- 2002-11-11 AR ARP020104319A patent/AR037299A1/es not_active Application Discontinuation
- 2002-11-20 JP JP2003545300A patent/JP2005511632A/ja active Pending
- 2002-11-20 EP EP02789069A patent/EP1453497A1/en not_active Withdrawn
- 2002-11-20 MX MXPA04004774A patent/MXPA04004774A/es not_active Application Discontinuation
- 2002-11-20 WO PCT/SE2002/002108 patent/WO2003043619A1/en not_active Ceased
- 2002-11-20 KR KR1020047007819A patent/KR20050044582A/ko not_active Withdrawn
- 2002-11-20 US US10/496,431 patent/US7358245B2/en not_active Expired - Fee Related
- 2002-11-20 NZ NZ532844A patent/NZ532844A/en unknown
- 2002-11-20 HU HU0402080A patent/HUP0402080A3/hu unknown
- 2002-11-20 CN CNA028233514A patent/CN1610542A/zh active Pending
- 2002-11-20 AU AU2002353700A patent/AU2002353700A1/en not_active Abandoned
- 2002-11-20 RU RU2004114843/15A patent/RU2280443C2/ru not_active IP Right Cessation
- 2002-11-20 PL PL02369402A patent/PL369402A1/xx unknown
- 2002-11-20 IL IL16174802A patent/IL161748A0/xx unknown
- 2002-11-20 CA CA002466916A patent/CA2466916A1/en not_active Abandoned
- 2002-11-20 BR BR0214319-4A patent/BR0214319A/pt not_active IP Right Cessation
-
2004
- 2004-05-17 ZA ZA200403785A patent/ZA200403785B/en unknown
- 2004-05-19 IS IS7272A patent/IS7272A/is unknown
- 2004-06-22 NO NO20042613A patent/NO20042613L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0402080A2 (hu) | 2005-02-28 |
| IL161748A0 (en) | 2005-11-20 |
| IS7272A (is) | 2004-05-19 |
| MXPA04004774A (es) | 2004-07-30 |
| HUP0402080A3 (en) | 2008-03-28 |
| US7358245B2 (en) | 2008-04-15 |
| BR0214319A (pt) | 2004-11-03 |
| NZ532844A (en) | 2005-12-23 |
| RU2280443C2 (ru) | 2006-07-27 |
| WO2003043619A1 (en) | 2003-05-30 |
| AU2002353700A1 (en) | 2003-06-10 |
| RU2004114843A (ru) | 2005-05-27 |
| ZA200403785B (en) | 2005-05-19 |
| KR20050044582A (ko) | 2005-05-12 |
| NO20042613L (no) | 2004-08-13 |
| TW200407110A (en) | 2004-05-16 |
| JP2005511632A (ja) | 2005-04-28 |
| US20040266861A1 (en) | 2004-12-30 |
| EP1453497A1 (en) | 2004-09-08 |
| PL369402A1 (en) | 2005-04-18 |
| CN1610542A (zh) | 2005-04-27 |
| CA2466916A1 (en) | 2003-05-30 |
| WO2003043619A8 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP044992A (es) | Inhibidores de la alquín-aril fosfodiesterasa-4 | |
| NI201100062A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
| ES2178943B1 (es) | Uso de compuestos organicos en el tratamiento de enfermedad pulmonar obstructiva cronica. | |
| BR0314603A (pt) | Uso de inibidores da sìntese de citoquina para o tratamento de distúrbios de olhos secos | |
| AR048588A1 (es) | Uso de inhibidores de la fosfodiesterasa de tipo iii (pde iii) para la reduccion del tamano del corazon en mamiferos que padecen insuficiencia cardiaca | |
| AR052221A1 (es) | Metodo para el tratamiento de la enfermedad poliquistosis renal | |
| BRPI0311275A2 (pt) | "composições de fenofibrato estáveis para administração oral, bem como uso das mesmas" | |
| CY2607B2 (en) | Synergistic combination of pde inhibitors and adenylate cyclase agonists or guanylcyclyse agonists | |
| AR037299A1 (es) | Uso para eltratamiento de la enfermedad de reflujo gastroesofagico | |
| ECSP055531A (es) | "nuevos derivados de glicósido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso" | |
| CR8102A (es) | Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa | |
| BRPI0413695A (pt) | derivados de naftiridina substituìda como inibidores do fator inibidor da migração de macrófagos e seu uso no tratamento de doenças humanas | |
| ECSP003682A (es) | Compuestos para el tratamiento de la isquemia | |
| NO20030929L (no) | Guanidinobenzamider som MC4-R agonister | |
| SE9800836D0 (sv) | New Compounds | |
| ECSP088973A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| AR109263A2 (es) | Composición que comprende moxidectina | |
| CL2008003939A1 (es) | Uso de escitalopram o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el tratamiento de ansiedad social (divisional de la solicitud 1799-00). | |
| GT200600163A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| AR039633A2 (es) | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
| CO5670327A2 (es) | Procedimiento para el tratamiento de trastornos de depresion y ansiedad mediante terapia de combinacion | |
| PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
| PE20020547A1 (es) | Uso de la tolterodina en tratamientos del asma | |
| AR026925A1 (es) | Nuevos derivados de azabiciclooctano utiles en el tratamiento de arritmias cardiacas | |
| AR030516A1 (es) | Uso de una combinacion de salmeterol y fluticasona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |